Cancer / Oncology/MGMT-methylated glioma
Central nervous system · subtype
MGMT-methylated glioma
Subtype of Glioblastoma
Clinical / Scientific
Promoter methylation silences MGMT, reducing repair of temozolomide-induced lesions and predicting greater alkylator benefit. It is a biomarker of DNA-repair state, not a separate histogenesis.
Core Biological Drivers
MGMT silencing
Impaired O6-methylguanine repair.
Key Pathways
Scientific explanation
Homologous-recombination defects (BRCA1/2 and related) create dependence on PARP-mediated repair. Mismatch-repair deficiency creates hypermutation and immune visibility.
Scientific explanation
TP53 encodes a stress-responsive factor controlling cell-cycle arrest, and metabolic adaptation. Loss or mutation is among the most common cancer events.
Scientific explanation
Intrinsic and extrinsic apoptotic programmes remove damaged cells. Evasion of is a hallmark, via BCL-2 family imbalance, death- decoys, or p53 loss.
Scientific explanation
recycles organelles and can support survival under nutrient or therapy stress. Context determines tumour-suppressive versus therapy-protective roles.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Energy stress
Energetic stress activates AMPK, which can restrain mTORC1. Biguanides and related tools map onto this axis in models.
Metabolic Vulnerabilities
Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.
Tumor Microenvironment
Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.
Metastasis Module
Same infiltrative GBM/glioma pattern.
Resistance Biology
Demethylation or selection of MGMT-expressing clones can restore repair.
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Target / Mechanism
Lysosomotropic agent that raises endosomal/autophagosomal pH, impairing flux. Combination trials in oncology have been mixed; blockade is not equivalent to proven benefit.
Cancer relevance
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Autophagy-modulation research combinations. Convergence: Autophagy.
Disulfiram
Target / Mechanism
ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.
Cancer relevance
ALDH and copper-dependent proteasome/NF-κB stress in models; clinical oncology remains limited.
ALDH / redox experimental context. Convergence: Cancer stemness, NF-κB, Oxidative stress.
Target / Mechanism
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Cancer relevance
disruption can trigger mitotic stress and in cell and animal models. This is not an established oncology use.
Experimental antimitotic / microtubule stress. Convergence: Apoptosis, p53.
Research Context
- GBM TMZ. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. https://doi.org/10.1056/NEJMoa043330
- GBM TCGA. Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. https://doi.org/10.1016/j.cell.2013.09.034
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.